2015 Fiscal Year Final Research Report
Developement of CTL-inducible West Nile virus vaccine using novel adjuvant
| Project/Area Number |
23590761
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hygiene
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011-04-28 – 2016-03-31
|
| Keywords | ウエストナイルウイルス / Ｅ蛋白質 / 組換え蛋白質 / 成分ワクチン / cross-presentation / CTL / 中和抗体 / 感染防御 |
|---|
| Outline of Final Research Achievements |
West Nile virus (WNV) is the human-infectious virus, which sometimes causes lethal encephalitis / meningitis, and vaccine and therapeutics for human use have not been developed yet. In this study, we focued on the envelope (E)protein, which can induce protective immunity. By immunizing mice with recombinant WNV E protein combined with γ - polyglutamic acid (γ-PGA) nano particles that is cytotoxic T lymphocyte (CTL) - inducible novel adjuvant, we confirmed that CTL as well as antibody specific for the epitopes on WNV E protein are efficiently induced. These results indicate that recombinant WNV E protein combined with γ-PGA nano particles have the potential for candidate of novel WNV vaccine. Furthermore, we have establihed human monoclonal antibodies, which possess neutralizing and protective activities agains WNV, from Japanese encephalitis virus (JEV) vaccine - immunized volunteers, using WNV E protein and ISAAC technology. They may be applicable for antibody-based therapeutics.
|
| Free Research Field |
感染免疫学
|
